Cargando…

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

Age-related macular degeneration (AMD) is still referred to as the leading cause of severe and irreversible visual loss world-wide. The disease has a profound effect on quality of life of affected individuals and represents a major socioeconomic challenge for societies due to the exponential increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt-Erfurth, Ursula, Chong, Victor, Loewenstein, Anat, Larsen, Michael, Souied, Eric, Schlingemann, Reinier, Eldem, Bora, Monés, Jordi, Richard, Gisbert, Bandello, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145443/
https://www.ncbi.nlm.nih.gov/pubmed/25136079
http://dx.doi.org/10.1136/bjophthalmol-2014-305702
_version_ 1782332179009765376
author Schmidt-Erfurth, Ursula
Chong, Victor
Loewenstein, Anat
Larsen, Michael
Souied, Eric
Schlingemann, Reinier
Eldem, Bora
Monés, Jordi
Richard, Gisbert
Bandello, Francesco
author_facet Schmidt-Erfurth, Ursula
Chong, Victor
Loewenstein, Anat
Larsen, Michael
Souied, Eric
Schlingemann, Reinier
Eldem, Bora
Monés, Jordi
Richard, Gisbert
Bandello, Francesco
author_sort Schmidt-Erfurth, Ursula
collection PubMed
description Age-related macular degeneration (AMD) is still referred to as the leading cause of severe and irreversible visual loss world-wide. The disease has a profound effect on quality of life of affected individuals and represents a major socioeconomic challenge for societies due to the exponential increase in life expectancy and environmental risks. Advances in medical research have identified vascular endothelial growth factor (VEGF) as an important pathophysiological player in neovascular AMD and intraocular inhibition of VEGF as one of the most efficient therapies in medicine. The wide introduction of anti-VEGF therapy has led to an overwhelming improvement in the prognosis of patients affected by neovascular AMD, allowing recovery and maintenance of visual function in the vast majority of patients. However, the therapeutic benefit is accompanied by significant economic investments, unresolved medicolegal debates about the use of off-label substances and overwhelming problems in large population management. The burden of disease has turned into a burden of care with a dissociation of scientific advances and real-world clinical performance. Simultaneously, ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up. However, definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management. The European Society of Retina Specialists offers expert guidance for diagnostic and therapeutic management of neovascular AMD supporting healthcare givers and doctors in providing the best state-of-the-art care to their patients. TRIAL REGISTRATION NUMBER: NCT01318941.
format Online
Article
Text
id pubmed-4145443
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-41454432014-09-02 Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA) Schmidt-Erfurth, Ursula Chong, Victor Loewenstein, Anat Larsen, Michael Souied, Eric Schlingemann, Reinier Eldem, Bora Monés, Jordi Richard, Gisbert Bandello, Francesco Br J Ophthalmol Review Age-related macular degeneration (AMD) is still referred to as the leading cause of severe and irreversible visual loss world-wide. The disease has a profound effect on quality of life of affected individuals and represents a major socioeconomic challenge for societies due to the exponential increase in life expectancy and environmental risks. Advances in medical research have identified vascular endothelial growth factor (VEGF) as an important pathophysiological player in neovascular AMD and intraocular inhibition of VEGF as one of the most efficient therapies in medicine. The wide introduction of anti-VEGF therapy has led to an overwhelming improvement in the prognosis of patients affected by neovascular AMD, allowing recovery and maintenance of visual function in the vast majority of patients. However, the therapeutic benefit is accompanied by significant economic investments, unresolved medicolegal debates about the use of off-label substances and overwhelming problems in large population management. The burden of disease has turned into a burden of care with a dissociation of scientific advances and real-world clinical performance. Simultaneously, ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up. However, definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management. The European Society of Retina Specialists offers expert guidance for diagnostic and therapeutic management of neovascular AMD supporting healthcare givers and doctors in providing the best state-of-the-art care to their patients. TRIAL REGISTRATION NUMBER: NCT01318941. BMJ Publishing Group 2014-09 /pmc/articles/PMC4145443/ /pubmed/25136079 http://dx.doi.org/10.1136/bjophthalmol-2014-305702 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Review
Schmidt-Erfurth, Ursula
Chong, Victor
Loewenstein, Anat
Larsen, Michael
Souied, Eric
Schlingemann, Reinier
Eldem, Bora
Monés, Jordi
Richard, Gisbert
Bandello, Francesco
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
title Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
title_full Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
title_fullStr Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
title_full_unstemmed Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
title_short Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
title_sort guidelines for the management of neovascular age-related macular degeneration by the european society of retina specialists (euretina)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145443/
https://www.ncbi.nlm.nih.gov/pubmed/25136079
http://dx.doi.org/10.1136/bjophthalmol-2014-305702
work_keys_str_mv AT schmidterfurthursula guidelinesforthemanagementofneovascularagerelatedmaculardegenerationbytheeuropeansocietyofretinaspecialistseuretina
AT chongvictor guidelinesforthemanagementofneovascularagerelatedmaculardegenerationbytheeuropeansocietyofretinaspecialistseuretina
AT loewensteinanat guidelinesforthemanagementofneovascularagerelatedmaculardegenerationbytheeuropeansocietyofretinaspecialistseuretina
AT larsenmichael guidelinesforthemanagementofneovascularagerelatedmaculardegenerationbytheeuropeansocietyofretinaspecialistseuretina
AT souiederic guidelinesforthemanagementofneovascularagerelatedmaculardegenerationbytheeuropeansocietyofretinaspecialistseuretina
AT schlingemannreinier guidelinesforthemanagementofneovascularagerelatedmaculardegenerationbytheeuropeansocietyofretinaspecialistseuretina
AT eldembora guidelinesforthemanagementofneovascularagerelatedmaculardegenerationbytheeuropeansocietyofretinaspecialistseuretina
AT monesjordi guidelinesforthemanagementofneovascularagerelatedmaculardegenerationbytheeuropeansocietyofretinaspecialistseuretina
AT richardgisbert guidelinesforthemanagementofneovascularagerelatedmaculardegenerationbytheeuropeansocietyofretinaspecialistseuretina
AT bandellofrancesco guidelinesforthemanagementofneovascularagerelatedmaculardegenerationbytheeuropeansocietyofretinaspecialistseuretina